VANI Stock Analysis: Buy, Sell, or Hold?
VANI - Vivani Medical, Inc. Common Stock (DE)
$1.19
0.00 (0.00%)
▲
5d:
+1.71%
30d:
-0.83%
90d:
+6.25%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When VANI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VANI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VANI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VANI is currently trading at $1.19, which is considered fair relative to its 30-day fair value range of $1.13 to $1.26.
Technical Outlook: Technically, VANI is in a downtrend. Immediate support is located at $1.13, while resistance sits at $1.33.
Market Sentiment: VANI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.75 (+215.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VANI is in a downtrend. Immediate support is located at $1.13, while resistance sits at $1.33.
Market Sentiment: VANI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.75 (+215.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.13 -
$1.26
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 215.1% below Wall St target ($3.75)
Trading Range Analysis
30-Day Trading Range
$1.13 -
$1.26
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.17
(14.5%)
Support & Resistance Levels
Support Level
$1.13
Resistance Level
$1.33
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.97
Wall Street Target
$3.75
(+215.1%)
Share & Embed Analysis
Last updated: June 24, 2026 11:58 AM ET
Data refreshes hourly during market hours. Next update: 12:58 PM
Data refreshes hourly during market hours. Next update: 12:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VANI showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gregg Williams
BUY
1587301 shares
2026-04-15
Gregg Williams
BUY
1575231 shares
2026-03-15
Gregg Williams
BUY
1351351 shares
2026-01-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
|
ALLO
Allogene Therapeutics Inc |
STRONG BUY
14 analysts |
$8 | 60 HOLD |
